Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants: 12 to \< 18 years old (Cohort 1), 6 to \< 12 years old (Cohort 2), 2 to \< 6 years old (Cohort 3), Weighing \> 8 kg to \< 2 years old (Cohort 4), and 28 days old to weighing ≤ 8 kg (Cohort 5).~* Undergone 1 allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor and source for hematological malignancies or disorders. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible.~* Clinically suspected Grade II to IV aGVHD as per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria, occurring after allo-HSCT and any GVHD prophylactic medication.~* Evidence of myeloid engraftment.~Exclusion Criteria:~* More than 1 allo-HSCT.~* Received more than 2 days of systemic corticosteroids for aGVHD before the first study drug administration.~* Presence of GVHD overlap syndrome.~* Presence of an active uncontrolled infection.~* Known HIV infection.~* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.~* Evidence of relapsed primary disease or have been treated for relapse after the allo-HSCT was performed.~* Any corticosteroid therapy for indications other than GVHD at doses \> 1 mg/kg once daily of methylprednisolone (or equivalent) within 7 days of the first study drug administration.~* Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.~* Receipt of JAK inhibitor therapy after allo-HSCT for any indication.~* Treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Itacitinib + Corticosteroids (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).